Experience the real world through multifocal corrections
Interested in ordering a SimVis Gekko?
Sim+Vis technology is backed by science
2EyesVision wins the startup competition at Transfiere
What are clinicians saying about #SimVisGekko?
Challenging the premium ophthalmology market with disruptive products
At 2EyesVision, we create, develop and market innovative technologies in ophthalmology, endeavoring to make the life of eye care professionals and their patients easier.
Our purpose is to improve the clinical practice in ophthalmology through new technologies that surprise the market. We strive to be a model of technology transfer and to demonstrate tangible value through our research, development and after-sales service.
Eye care technology
Every person is unique, one lens can be suitable for one individual but not necessarily for another. That’s why using the visual simulator SimVis Gekko is so important!
Seeing is believing
Know your patients' reaction to multifocality before treatment
With SimVis Gekko, every patient can have, before prescription, a non-invasive and personalized assessment on how their vision will be with any presbyopic correction. It can be applied to:
Intraocular lens implantation
Contact lens fitting
Laser presbyopic surgery
Fine-tuning the right binocular combination
Reduce the uncertainty before surgery and enrich the doctor-patient dialogue
Presbyopia affects everyone above 45 years old. Most people will also develop cataracts. Among the available treatment options, multifocal corrections with contact lenses or intraocular lenses have become a good alternative.
“Being able to simulate potential visual performance of my patients with different available intraocular lenses has been one of my greatest dreams as a refractive cataract surgeon.”
What is the visual simulator #SimVisGekko?
The power of truth
The Sim+Vis Technology™ was developed at the Visual Optics and Biophotonics Lab of the Spanish National Research Council (CSIC), a worldwide recognized research institution, and 2EyesVision has licensed the patents with global exclusivity. More than 25 scientific articles have been published after 10+ years of joint research and development: